This research study pairs a new imaging approach with standard bevacizumab treatment. Specifically, the trial is evaluating the use of two contrast-enhanced MRI exams, one done before treatment begins and the other after two weeks. There is evidence from smaller trials that early use of contrast MRIs to measure changes in the amount of blood in the tumor is a better and faster way than the current method to identify which patients are benefiting from bevacizumab. This earlier measure could also benefit those for whom the therapy is not working, allowing them to move on to try other treatments. Currently, a response is measured after three months of treatment.

Physician and Research Staff Educational Materials:

These materials are intended for promotional use among health care professionals and are NOT intended for use as patient educational materials.

Physicians and Locations Interested in Opening the Trial: Send an email

Additional Information on Cancer.gov: Displayed below is an interactive view of the study record as it appears in the government registry. If you are experiencing technical difficulties with this view, follow this link. The trial is registered on clinicaltrials.gov as record NCT03115333.